Physician profile
Stephen Gale
NPI 1407862410
$686.94
in general payments reported to CMS, 2019-2025
10 companies · $215 in 2025
The $215 reported for 2025 was less than what a typical Surgical Critical Care provider received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.91 · 2021: $90.93 · 2022: $150 · 2023: $96.60 · 2024: $117 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $229.63 | 2023-2025 | Enseal, Echelon; Endopath, Stratafix |
| Shionogi INC | $92.94 | 2022-2024 | Fetroja |
| Teleflex LLC | $69.63 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.22 | 2021-2023 | Gattex |
| Depuy Synthes Sales INC. | $62.59 | 2022 | |
| Hemosonics LLC | $59.47 | 2024-2025 | Qunatra Qplus System, Quantra Qplus System |
| Kerecis Limited | $37.47 | 2022-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Medinc of Texas | $33.53 | 2025 | |
| Integra Lifesciences Corporation | $19.55 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Edwards Lifesciences Corporation | $16.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Gale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.